News
May 28, 2026
The Key Hereditary Transthyretin Amyloidosis Companies in the market include - Alnylam Pharmaceuticals, Ionis Pharmaceuticals, AstraZeneca, Pfizer, Intellia…
May 28, 2026
More recent clinical trials also show less advanced disease in patientsPeople with transthyretin amyloid cardiomyopathy (ATTR-CM) enrolled in more recent…
May 27, 2026
AbstractIntroductionTimely diagnosis and treatment are essential for improving outcomes and quality of life in patients with transthyretin (ATTR) amyloidosis. Early…
May 27, 2026
Medison Pharma’s Amvuttra (vutrisiran) has entered Korea’s reimbursement system for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), raising…
May 27, 2026
AbstractAcute heart failure (AHF) represents a major global health challenge, with a substantial impact on survival, morbidity, and health care resource utilization…
May 27, 2026
AbstractBACKGROUND:Cardiac amyloidosis (CA) is an underdiagnosed yet treatable cause of heart failure in which timely diagnosis is essential to initiate life-…
May 27, 2026
AbstractBackground and ObjectiveWe assessed the consistency of serum transthyretin (TTR) knockdown with the RNA interference therapeutic vutrisiran across…
May 26, 2026
There were no safety findings associated with vitamin A deficiency following treatment with patisiran or vutrisiran in patients with transthyretin (TTR) amyloidosis…
May 26, 2026
AbstractSystemic amyloid light-chain (AL) amyloidosis is a multisystem disorder caused by extracellular deposition of monoclonal immunoglobulin light chains.…
May 26, 2026
AbstractWild-type transthyretin cardiac amyloidosis (ATTRwt) is an underrecognized cause of heart failure that often mimics hypertensive or nonischemic…